Search

To reduce obesity and cardiovascular risk, a combination of low carbohydrate diet and sport is a good choice in otherwise healthy individuals. However, among patients with type 1 diabetes mellitus (T1DM), consuming a minimum of 130 g carbohydrates per day is recommended, and the desire to exercise decreased as well. We wanted to demonstrate that a low carbohydrate diet during physical activity in T1DM patients is safe with the right choice of insulin dosing and reduces the development of both short- and long-term complications. To this end, we collected data from T1DM patients on a normal and low carbohydrate diet using a questionnaire as well as measured blood glucose levels while exercising in healthy and T1DM patients. The main benefit of the diet was that it provided a safe exercise option with more stable blood glucose levels and lower bolus insulin requirements. Our data support that the emergence of new types of insulins, tissue glucose sensors, and pumps has provided the conditions for a freer, less complicated life for patients with T1DM, for which the combined use of a normal and low carbohydrate diet can be an important tool.

Previously it was shown that the use of regulatory peptides of the glyprolin family helps to normalize the hemostasis system and blood glucose levels in experimental resistant hyperglycemia in rats, similar to type 2 diabetes mellitus in humans. It is also known that the anticoagulant heparin inhibits blood coagulation and exhibits a hypoglycemic effect in the body.The aim of the study is to obtain a complex of the Pro-Gly-Pro-Leu (PGPL) peptide and the unfractionated heparin, to study its effect on glucose and anticoagulant fibrinolytic properties and show its ability to restore the impaired functions of the insular and coagulating blood systems in experimental hyperglycemia in rats.Materials and Methods. Laboratory Wistar male rats, intact and with experimentally induced hyperglycemia, were used in the experiment. A complex compound of PGPL and heparin was created with a component ratio of 1:1 (mol/mol), which was administered intranasally to hyperglycemic rats once a day for 5 days at the dose of 1 mg/kg. Similarly, the constituent parts of the complex were administrated in equivalent amounts. The anticoagulant activity was determined by the test of activated partial thromboplastin time, fibrinolysis parameters - by tests of total, enzymatic and non-enzymatic fibrinolytic activities, as well as the activity of a tissue plasminogen activator. In addition, blood glucose was measured using special test strips. Results. The use of the PGPL-heparin complex in the animals with hyperglycemia led to normalization of blood glucose levels, an increase in the anticoagulant and fibrinolytic background of blood plasma. These effects persisted for 6 days after the cancellation of the peptide-heparin complex administration to rat.Conclusion. In the development of experimental hyperglycemia, the PGPL complex with heparin exhibits a combined hypo-glycemic, anticoagulant and fibrinolytic enzymatic and non-enzymatic nature of the effect. In the future, the studied peptide-heparin complex can be used for the prevention and treatment of type 2 diabetes mellitus, complicated by increased blood coagulation.